<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03879057</url>
  </required_header>
  <id_info>
    <org_study_id>CGOG-3006/2018-012-00CH2</org_study_id>
    <nct_id>NCT03879057</nct_id>
  </id_info>
  <brief_title>Trial of Surufatinib Combined With JS001 in the Treatment of Advanced Solid Tumors</brief_title>
  <official_title>Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surufatinib Combined With JS001 in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, phase I study evaluating safety, tolerability, pharmacokinetics and&#xD;
      efficacy of Surufatinib combined with the humanized anti-PD-1 antibody JS001 in patients with&#xD;
      solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>adverse events</measure>
    <time_frame>1 year</time_frame>
    <description>Safety of participants followed for the duration of hospital stay, an expected average of 1 week</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum tolerated dose</measure>
    <time_frame>4 week</time_frame>
    <description>tolerability during the treatment of first cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months</time_frame>
    <description>The number of cases in which tumor size is reduced to PR or CR / the total number of evaluable cases (%). In the event of PR or CR, the subjects should confirm it no less than 4 weeks after the first evaluation. CT/MRI will be performed every 2 cycles of treatment by RECIST 1.1(each cycle is 21 days))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to treatment failure(TTF)</measure>
    <time_frame>1 month</time_frame>
    <description>From date of enrollment until the date of tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>8 days</time_frame>
    <description>Pharmacokinetic profile in terms of observed maximum plasma concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve From Time Zero Extrapolated to Infinity (AUC(0-inf))</measure>
    <time_frame>8 days</time_frame>
    <description>Pharmacokinetic profile in terms of plasma concentration-time curve from time zero extrapolated to infinity, AUC(0-inf)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Surufatinib 200mg/JS001 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surufatinib at a dose of 200mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001） injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Surufatinib 300mg/JS001 240mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surufatinib at a dose of 300mg Qd, with humanized anti-PD-1 monoclonal antibody（JS001) injected intravenously 240mg per 3 weeks until disease progresses or unacceptable tolerability occurs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Surufatinib/humanized anti-PD-1 monoclonal antibody</intervention_name>
    <description>humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.</description>
    <arm_group_label>Surufatinib 200mg/JS001 240mg</arm_group_label>
    <arm_group_label>Surufatinib 300mg/JS001 240mg</arm_group_label>
    <other_name>Surufatinib/JS001</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must have read, understood, and provided written informed consent voluntarily. Willing&#xD;
             to adhere to the study visit schedule and the prohibitions and restrictions specified&#xD;
             in this protocol.&#xD;
&#xD;
          2. Male and Female aged between 18 and 75 years are eligible;&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;&#xD;
&#xD;
          4. Histologic diagnosis of locally advanced or metastatic unresectable solid tumors&#xD;
             (neuroendocrine tumors, liver carcinoma, gastric carcinomas considered with priority);&#xD;
&#xD;
          5. Failed after standard treatment (disease progression or intolerable for toxic side&#xD;
             effects) or no effective to treatment;&#xD;
&#xD;
          6. For liver carcinoma with Child-Pugh of grade A and grade B (≤ 7 points);&#xD;
&#xD;
          7. Radiographic evidence of disease rogression by RECIST criteria on or after last&#xD;
             anti-cancer therapy within 6 months; If the single lesion previously received&#xD;
             radiation, ablation, there must be an imaging identification for disease progression;&#xD;
&#xD;
          8. Predicted survival &gt;=3 months;&#xD;
&#xD;
          9. At least 1 measurable lesion (only 1 measurable lymph node lesion is excluded)&#xD;
             (routine CT scan &gt;=20mm, spiral CT scan &gt;=10mm, no prior radiation to measurable&#xD;
             lesions);&#xD;
&#xD;
         10. Screening laboratory values must meet the following criteria (within past 14 days):&#xD;
             hemoglobin ≥ 9.0 g/dL; neutrophils ≥ 1500 cells/ μL; platelets ≥ 100 x 10^3/ μL; total&#xD;
             bilirubin ≤ 1.5 x upper limit of normal (ULN); aspartic transaminase (AST) and alanine&#xD;
             transaminase (ALT) ≤ 2.5 x ULN without, and ≤ 5 x ULN with hepatic metastasis; serum&#xD;
             creatinine ≤1╳ULN, creatinine clearance &gt;50ml/min (CockcroftGault equation) PT/INR,&#xD;
             aPTT≤1.5 x ULN;&#xD;
&#xD;
         11. Males or female of childbearing potential must: agree to use using a reliable form of&#xD;
             contraception (eg, oral contraceptives, intrauterine device, control sex desire,&#xD;
             double barrier method of condom and spermicidal) during the treatment period and for&#xD;
             at least 12 months after the last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The toxicity associated with previous anti-tumor treatment has not recovered to&#xD;
             ≤CTCAE1, except for peripheral neurotoxicity and alopecia ≤CTCAE2 caused by&#xD;
             oxaliplatin;&#xD;
&#xD;
          2. Had other malignant tumors in the past 5 years (except for basal cell carcinoma or&#xD;
             squamous cell carcinoma, cervical carcinoma in situ that have been effectively&#xD;
             controlled);&#xD;
&#xD;
          3. Evidence with active CNS disease;&#xD;
&#xD;
          4. Prior treatment with chemotherapy, biological immunotherapy, targeted therapy, Chinese&#xD;
             herbal medicine within 2 weeks.&#xD;
&#xD;
          5. Prior treatment with radical radiation within 4 weeks&#xD;
&#xD;
          6. Prior treatment with antiPD1/PDL1/PDL2/CTLA-4 antibody or Sulfatinib;&#xD;
&#xD;
          7. Prior treatment with corticosteroids (dose &gt; 10 mg/day prednisone or other hormones)&#xD;
             or other immunosuppressive agents within 2 weeks, nasal or inhalation in allowed (dose&#xD;
             &gt; 10 mg/day prednisone or other hormones).&#xD;
&#xD;
          8. Patients with any active autoimmune disease or a documented history of autoimmune&#xD;
             disease, or history of syndrome that required systemic steroids or immunosuppressive&#xD;
             medications, such as hypophysitis, pneumonia, colitis, hepatitis, nephritis,&#xD;
             hyperthyroidism or hypothyroidism;&#xD;
&#xD;
          9. Prior live vaccine therapy within past 4 weeks;&#xD;
&#xD;
         10. Prior major surgery within past 4 weeks (diagnostic surgery excluded);&#xD;
&#xD;
         11. Uncontrolled malignant pleural effusion, ascites or pericardial effusion;&#xD;
&#xD;
         12. Hypertension that is not controlled by the drug, and is defined as: SBP≥140 mmHg&#xD;
             and/or DBP≥90 mmHg;&#xD;
&#xD;
         13. The patient currently has disease or condition that affects the absorption of the&#xD;
             drug, or the patient cannot be administered orally;&#xD;
&#xD;
         14. Received a potent inducer or inhibitor of CYP3A4 within 2 weeks, or continue receiving&#xD;
             these drugs during the study;&#xD;
&#xD;
         15. Digestive tract disease such as gastric and duodenal active ulcer, ulcerative colitis&#xD;
             or unresected tumor, or other conditions determined by the investigator that may cause&#xD;
             gastrointestinal bleeding and perforation;&#xD;
&#xD;
         16. Evidence of bleeding tendency or history within 2 months, or thromboembolic event&#xD;
             (including a stroke event and/or a transient ischemic attack) occurred within 12&#xD;
             month;&#xD;
&#xD;
         17. Severe, uncontrolled medical condition that would affect patients' compliance or&#xD;
             obscure the interpretation of toxicity determination or adverse events, including&#xD;
             active severe infection, uncontrolled diabetes, angiocardiopathy (heart failure &gt;&#xD;
             class II NYHA, LVEF &lt;50%, myocardial infarction, unstable arrhythmia or unstable&#xD;
             angina within past 6 months, cerebral infarction within past 3 months) or pulmonary&#xD;
             disease ( interstitial pneumonia, obstructive pulmonary disease or symptomatic&#xD;
             bronchospasm);&#xD;
&#xD;
         18. Clinically significant severe electrolyte abnormality judged by investigator ;&#xD;
&#xD;
         19. Active infection or unexplained fever during the screening period (temperature &gt;38.5C)&#xD;
&#xD;
         20. History with tuberculosis who are receiving or have received anti-TB treatment within&#xD;
             1 year.&#xD;
&#xD;
         21. Pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonitis,&#xD;
             drug-associated pneumonia, severe impaired lung function, etc; Radiation pneumonitis&#xD;
             in the radiotherapy area is allowed;&#xD;
&#xD;
         22. Positive tests for HIV, HCV, HBsAg or HBcAb with positive test for HBV DNA&#xD;
             (&gt;2000IU/ml);&#xD;
&#xD;
         23. Prior antitumor therapy (including corticosteroids and immunotherapy) or participation&#xD;
             in other clinical trials within past 4 weeks, or have not recovered from toxicities&#xD;
             since the last treatment;&#xD;
&#xD;
         24. Pregnant or nursing;&#xD;
&#xD;
         25. Hypersensitivity to Sulfatinib or recombinant humanized antiPD1 monoclonal Ab;&#xD;
&#xD;
         26. Underlying medical condition that, in the Investigator's opinion, would increase the&#xD;
             risks of study drug administration or obscure the interpretation of toxicity&#xD;
             determination or adverse events.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lin Shen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lin Shen</last_name>
    <phone>86-10-88196561</phone>
    <email>linshenpku@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Cancer Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lin Shen</last_name>
      <phone>86-10-88196561</phone>
      <email>linshenpku@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>December 28, 2018</study_first_submitted>
  <study_first_submitted_qc>March 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2019</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Shen Lin</investigator_full_name>
    <investigator_title>MD, Professor, Chief of Department of GI Oncology, Peking University Cancer Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

